Open access · OA
via Europe PMC
The Development of Cellular Aging Models Based on AD-MSCs.
Elizova NV, Zhivodernikov IV, Vasilyev VS, Tolkachev YD, Markina YV, Markin AM, Kirichenko TV.
Cells · 2026
Abstract
Cellular senescence(definition) of adipose tissue-derived mesenchymal stromal cells (AD-MSCs) is associated with chronic low-grade inflammation, metabolic dysfunction, and impaired adipogenesis contributing to the development of obesity, insulin resistance, and the progression of age-associated diseases. The aim of this study was to develop a model of cellular aging based on AD-MSCs to study the senolytic efficacy of the natural fisetin preparation for the subsequent development of geroprotective therapeutic strategies. The senescent markers SA-β-gal, SASP factors, and cell cycle arrest markers p16, p21, and p53 were assessed in models of replicative and stress-induced aging of AD-MSCs. H<sub>2</sub>O<sub>2</sub> was identified as the most effective inducer of AD-MSC cellular senescence in comparison with LPS. It has been shown in the model of H<sub>2</sub>O<sub>2</sub>-induced senescence of AD-MSCs that the proportion of SA-β-gal+ cells was 2.0 (0.7)% in non-stimulated AD-MSCs, 81.7 (12.1)% in H<sub>2</sub>O<sub>2</sub>-stimulated AD-MSCs, and 19.1 (5.2)% and 13.0 (3.2)% after short-term (24 h) and long-term (7 days) fisetin treatment, respectively, indicating that fisetin treatment was associated with a lower proportion of SA-β-gal+ cells. Fisetin treatment resulted in a statistically significant decrease in the secretion of MCP-1, especially during long-term incubation. IL-1β showed a significant decrease after 7 days of fisetin treatment compared to H<sub>2</sub>O<sub>2</sub>, but the effect at 24 h was only significant in the group of 7 days of fisetin treatment. Fisetin treatment was also associated with higher p53 and p21 concentrations. Thus, in the present study, a model of H<sub>2</sub>O<sub>2</sub>-induced cellular senescence of AD-MSCs was developed, which can be used to evaluate the geroprotective potential of senotherapeutic preparations; fisetin warrants further evaluation as a potential senotherapeutic agent in this model.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- Europe PMC
- DOI
- 10.3390/cells15181634
- Canonical
- link ↗
- Fetched
- 2026-10-06 MST
Cite this
APA
NV, E., IV, Z., VS, V., YD, T., YV, M., AM, M., & TV., K. (2026). The Development of Cellular Aging Models Based on AD-MSCs. <em>Cells</em>. https://doi.org/10.3390/cells15181634
Vancouver
NV E, IV Z, VS V, YD T, YV M, AM M, et al. The Development of Cellular Aging Models Based on AD-MSCs. Cells. 2026. doi:10.3390/cells15181634.
BibTeX
@article{elizova2026TheDev,
title = {The Development of Cellular Aging Models Based on AD-MSCs.},
author = {Elizova NV and Zhivodernikov IV and Vasilyev VS and Tolkachev YD and Markina YV and Markin AM and Kirichenko TV.},
journal = {Cells},
year = {2026},
doi = {10.3390/cells15181634},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Cells 2026
Open access · CC-BY
The Development of Cellular Aging Models Based on AD-MSCs
Stem Cell Research & Therapy 2025
Open access · CC-BY
Targeting cellular senescence in progenitor cells as a strategy to enhance bone regeneration by cell therapies: a systematic review of pre-clinical investigations
International Journal of Molecular Sciences 2026
Open access · CC-BY
Cellular Senescence and the SASP in HFpEF: Pathogenic Mechanisms and Therapeutic Targeting
International journal of molecular sciences 2026
Citation only
Cellular Senescence and the SASP in HFpEF: Pathogenic Mechanisms and Therapeutic Targeting.
I P Pavlov Russian Medical Biological Herald 2025
Citation only
Pathogenetic markers of cellular senescence
Bone Research 2025
Open access · CC-BY